Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulatory concerns in human gene therapy.

S L Epstein1

  • 1Molecular Immunology Laboratory, Division of Biochemistry and Biophysics, FDA, CBER, Bethesda, MD 20892.

Human Gene Therapy
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Gene therapy·2015
Same author

The I-J dilemma: new developments.

Immunology today·2014
Same author

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.

International immunology·1999
Same author

Mechanism of protective immunity against influenza virus infection in mice without antibodies.

Journal of immunology (Baltimore, Md. : 1950)·1998
Same author

Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression.

The Journal of experimental medicine·1997
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
Same journal

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same journal

<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

Human gene therapy·2026
See all related articles

Human gene therapy is under investigation, involving biological products for patients. This paper explains the regulatory process and data requirements from the Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA).

Area of Science:

  • Biotechnology
  • Medical Regulation
  • Human Therapeutics

Background:

  • Human gene therapy is an emerging investigational field.
  • This therapy involves administering biological products to patients.
  • Regulatory oversight is crucial for ensuring safety and efficacy.

Purpose of the Study:

  • To explain the regulatory process for human somatic cell and gene therapy.
  • To provide the scientific and regulatory basis for data requests.
  • To clarify the role of the Center for Biologics Evaluation and Research (CBER).

Main Methods:

  • Review of CBER's "Points to Consider" document.
  • Explanation of the regulatory framework for gene therapy products.
  • Discussion of data requirements for investigational therapies.
Keywords:
Biomedical and Behavioral ResearchGenetics and ReproductionLegal ApproachNational Institutes of HealthPoints to Consider in Human Somatic Cell Therapy and Gene TherapyRecombinant DNA Advisory Committee

Related Experiment Videos

Main Results:

  • Gene therapy applications require rigorous data submission.
  • CBER's guidelines provide a framework for product development.
  • Understanding the regulatory basis is essential for researchers.

Conclusions:

  • The CBER regulatory process ensures scientific and safety standards for gene therapy.
  • Compliance with FDA guidelines is necessary for investigational gene therapy.
  • This paper clarifies the rationale behind regulatory data requests.